Atopic Dermatitis – ACT17207

A Phase 2, randomized, double-blind, placebo controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids.

Register Today!

Trial Information

Start DateNovember 2022
End Date~ June 2023
Trial Duration~20 weeks
Number of Visits6
Lead CRCJessica Richer

For additional information
on this trial contact: